Agentic AI improves drug development by automating patient recruitment, protocol optimization, real-time adverse event monitoring, and drug candidate identification.1
IQVIA highlights agentic AI compressing clinical trial timelines through outcome simulations, site selection, and compliance automation (Nov 2025).2
Salesforce notes agentic AI's role in target identification, compound screening, predictive modeling, and patient-trial matching across pharma lifecycle.3
Insilico Medicine launched PandaClaw on March 23, 2026, enabling biologists to use AI agents for target discovery and hypothesis building via natural language, reducing preclinical timelines to 12-18 months.4
Agentic AI supports low-risk areas like data review configuration, content generation (e.g., informed consent), and trial master file management, with human-in-the-loop oversight.16
Sources:
1. https://globalforum.diaglobal.org/issue/august-2025/next-steps-in-artificial-intelligence-agentic-ai/
2. https://www.iqvia.com/blogs/2025/11/driving-faster-clinical-timelines-and-patient-impact-with-agentic-ai
3. https://www.salesforce.com/life-sciences/artificial-intelligence/agentic-ai-in-pharma/
4. https://www.prnewswire.com/news-releases/insilico-medicine-launches-pandaclaw-empowering-biologists-with-agentic-ai-for-therapeutic-discovery-302722015.html
6. https://pharmaphorum.com/rd/complexity-cohesion-ais-growing-role-building-seamless-clinical-operations